Mark Levin
Partner @ Third Rock Ventures
Boston, United States
Mark Levin is a Series A investor at Third Rock Ventures in Boston focused on Health Care and Medical Device. Mark Levin is the Interim CEO, a member of the Board of Directors, and a Partner at Third Rock Ventures. He is an industry visionary with 40 years of experience, including more than 30 years of launching and building leading biotech companies. Mr. Levin co-founded Third Rock Ventures in 2007 and focuses on the formation, development, and businessstrategy of its portfolio companies, as well as actively identifying and evaluating new investments.Before Third Rock, Mr. Levin was co-founder of Mayfield Fund's life sciences effort, where he was also the founding CEO of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells, and Millennium Pharmaceuticals.Mr. Levin served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Eli Lilly and Genentech. He is a member of the National Academy of Engineering and the Friends of Personalized Medicine, and he co-founded the Possible Project in Cambridge, Mass.Mr. Levin holds an M.S. in chemical and biochemical engineering from Washington University.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Mark Levin invests in
Stages Mark Levin invests in
Countries Mark Levin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (40%)
- Medical Device 2 (40%)
- Medical 1 (20%)
- Biopharma 1 (20%)
Stage
- Series A 1 (20%)
- Series B 1 (20%)
- Series C 1 (20%)
- Series D 1 (20%)
- Funding Round 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $55M / Jun 17, 2025 | ||
| Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $34M / Series D / Jul 01, 2014 | ||
| NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. | $34M / Series B / Mar 18, 2014 | ||
| Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $10.7M / Series C / Mar 01, 2013 | ||
| NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. | $33M / Series A / Oct 14, 2010 |
Co-Investors
About Third Rock Ventures
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Third Rock Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cary Pfeffer
Partner
|
|||
|
Jeff Tong
Partner
|
|||
Jigar Raythatha
Partner
|
|||
|
Mark Levin
Partner
|
|||
Reid Huber
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Mark Levin invest in?
Mark Levin invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mark Levin?
Public channels for Mark Levin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Mark Levin last invest?
The most recent investment recorded for Mark Levin closed in Jun 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
